Antihypertension drug may help patients with noncancerous brain tumors affecting hearing
(Massachusetts General Hospital) New research led by investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear indicates that the blood pressure drug losartan may benefit patients with neurofibromatosis type 2. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news
Optic nerve firing may spark growth of vision-threatening childhood tumor
(NIH/National Institute of Neurological Disorders and Stroke) In a study of mice, researchers showed how the act of seeing light may trigger the formation of vision-harming tumors in young children who are born with neurofibromatosis type 1 (NF1) cancer predisposition syndrome. The research team, funded by the National Institutes of Health, focused on tumors that grow within the optic nerve, which relays visual signals from the eyes to brain. They discovered that the neural activity which underlies these signals can both ignite and feed the tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 1, 2021 Category: Cancer & Oncology Source Type: news
Children's Tumor Foundation announces revised diagnostic criteria for NF1
(Children's Tumor Foundation) The Children's Tumor Foundation (CTF) today announced the publication of updated diagnostic criteria for the genetic disorder neurofibromatosis type 1 (NF1) in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics. The new publication is the result of an extensive, multi-year collaborative effort of over 90 leading neurofibromatosis (NF) experts from around the globe, and is aimed at improving the accuracy and earlier diagnosis of NF1 in patients. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 19, 2021 Category: Biology Source Type: news
What Are Some Etiologies for Intellectual Disability?
Discussion
“Intellectual disability (ID) is a neurodevelopmental disorder that is characterized by deficits in both intellectual functioning and adaptive function whose onset is in the development period.” Global developmental delay (GDD) is used to describe children from 0-5 years old with significant delays in 2 or more developmental areas. These delays may be transient but up to 2/3 of children with GDD will have ID. Overall 1-3% of the general population has ID which makes it very common.
Most children with GDD/ID are identified because of delays in meeting milestones or general academic achievement. ID pat...
Source: PediatricEducation.org - May 3, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Risk factors for bullying victimization in children with neurofibromatosis type 1 (NF1) - Stavinoha PL, Solesbee C, Swearer SM, Svoboda S, Klesse LJ, Holland AA.
Neurofibromatosis type 1 (NF1) is an autosomal disorder associated with numerous physical stigmata. Children with NF1 are at known risk for attention-deficit/hyperactivity disorder (ADHD), academic struggles, and significant social difficulties and adverse... (Source: SafetyLit)
Source: SafetyLit - March 12, 2021 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
NIH Director Francis Collins Is Fighting This Coronavirus While Preparing for the Next One
In May 2020, Dr. Francis Collins, the longtime head of the National Institutes of Health (NIH), was called to the White House to meet with Jared Kushner, the then President’s son-in-law and adviser, and Dr. Deborah Birx, the head of the White House Coronavirus Task Force. A few weeks earlier, Congress had given the NIH $1.5 billion to try to speed up the process of developing new diagnostic tests for COVID-19, and the White House, which was dubious about increasing the rate of testing, wanted to know more about what the NIH was doing.
Collins is technically the boss of Dr. Anthony Fauci, but during the pandemic he ha...
Source: TIME: Health - February 4, 2021 Category: Consumer Health News Authors: Belinda Luscombe Tags: Uncategorized COVID-19 feature Magazine Source Type: news
Physical therapy to address fall risk in an individual with neurofibromatosis - Adams RB, Dudley JT, Struessel TS.
BACKGROUND: While physical therapy may help improve function and quality of life in patients with neurofibromatosis (NF), a standard of care remains to be established. This case report describes the physical therapy management of an individual with NF who ... (Source: SafetyLit)
Source: SafetyLit - January 28, 2021 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
Study demonstrates efficacy of new treatment for neurofibromatosis type 1-related tumors
(Children's Hospital of Philadelphia) Based on preclinical studies of an investigational drug to treat peripheral nerve tumors, researchers at Children's Hospital of Philadelphia (CHOP) as part of the Neurofibromatosis Clinical Trials Consortium have shown that the drug, cabozantinib, reduces tumor volume and pain in patients with the genetic disorder neurofibromatosis type 1 (NF1). The results of the Phase 2 clinical trial, co-chaired by Michael J. Fisher, MD at CHOP, were published recently in Nature Medicine. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 14, 2021 Category: International Medicine & Public Health Source Type: news
GIST of the Duodenum and Proximal Jejunum GIST of the Duodenum and Proximal Jejunum
What did imaging reveal about the cause of flank pain in this patient with a history of neurofibromatosis type 1?Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 1, 2020 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news
Hack for NF winning projects announced
(Children's Tumor Foundation) Hack for NF, a hackathon for neurofibromatosis research hosted by the Children's Tumor Foundation, today announced the winners of the 2020 virtual event that brought together healthcare startups, developers, solutions architects, and hackathon enthusiasts for six weeks to drive scientific and medical innovation and improve the lives of patients living with neurofibromatosis and other rare diseases. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news
Bringing Brigatinib to Neurofibromatosis Type-2 Patients: From...
Children’s Tumor Foundation and Takeda Pharmaceuticals Launch INTUITT for NF2 in Partnership with 6 Leading Medical Centers(PRWeb May 29, 2020)Read the full story at https://www.prweb.com/releases/bringing_brigatinib_to_neurofibromatosis_type_2_patients_from_promising_potential_to_platform_clinical_trial/prweb17157522.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 29, 2020 Category: Pharmaceuticals Source Type: news
New targets for childhood brain tumors identified
(Washington University School of Medicine) People with the genetic condition neurofibromatosis type 1 (NF1) are prone to developing tumors on nervous system tissue. A new study from Washington University School of Medicine in St. Louis has found that the development and growth of such tumors are driven by nearby noncancerous neurons and immune cells. The findings point to potential new therapeutic targets for people with NF1. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2020 Category: International Medicine & Public Health Source Type: news
FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1
Title: FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1Category: Health NewsCreated: 4/14/2020 12:00:00 AMLast Editorial Review: 4/15/2020 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 15, 2020 Category: Cancer & Oncology Source Type: news
FDA Approves Koselugo for Pediatric Neurofibromatosis Type 1
TUESDAY, April 14, 2020 -- Koselugo (selumetinib) has received the first approval for treatment of neurofibromatosis type 1 (NF1) in children ages 2 years and older, the U.S. Food and Drug Administration announced Friday.
Approved specifically for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 14, 2020 Category: General Medicine Source Type: news
FDA Approves Koselugo (selumetinib) for Pediatric Patients with Neurofibromatosis Type 1 Plexiform Neurofibromas
13 April 2020 -- AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck& Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo (selumetinib)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 13, 2020 Category: Drugs & Pharmacology Source Type: news
